ARCA programs to expand development plan for Gencaro in atrial fibrillation ARCA biopharma.

ARCA programs to expand development plan for Gencaro in atrial fibrillation ARCA biopharma, Inc. , a biopharmaceutical firm developing genetically-targeted therapies for cardiovascular diseases, announced that it is planning to expand the advancement of Gencaro today, its lead cardiovascular drug candidate, to atrial fibrillation, a disease that affects a lot more than 2.4 million sufferers in the usa. Subject to obtaining additional funding, the Company anticipates initiating individual enrollment of a Phase 3 scientific trial in the initial half of 2012 to evaluate Gencaro in patients who’ve symptomatic atrial fibrillation and heart failure with reduced remaining ventricular ejection fraction .This year's winning paper is: Use of a Bioactive Scaffold to Stimulate Recovery also Minimizes Post-Traumatic Osteoarthritis after Procedure by Martha M. Murray MD and Braden C. Fleming PhD. This 12 months's winning paper was from the Hospital for Special Medical procedures in NY and titled Presentation Development and Validation of a Pediatric Sports Activity Rating Level. Research authors included: Peter D. Fabricant MD, MPH, Alex Robles BS, Timothy Downey-Zayas BS1, Huong T. Do MA, Robert G. Marx MD, MSc, Roger F. Widmann MD, and Daniel W. Green MD, MS. O'Donoghue Sports Injury Research Award This award is given annually to the very best general paper that deals with clinical based research or human in-vivo research.